Get the Stockscreener App
0.4123
3.05%
0.0122
After Hours:
.41
-0.0023
-0.56%
Ensysce Biosciences Inc stock is traded at $0.4123, with a volume of 140.70K.
It is up +3.05% in the last 24 hours and up +2.31% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$0.4001
Open:
$0.405
24h Volume:
140.70K
Relative Volume:
0.01
Market Cap:
$8.02M
Revenue:
$4.71M
Net Income/Loss:
$-11.79M
P/E Ratio:
-0.1231
EPS:
-3.3492
Net Cash Flow:
$-9.72M
1W Performance:
-10.00%
1M Performance:
+2.31%
6M Performance:
-26.08%
1Y Performance:
-81.76%
1-Day Range:
$0.4008
$0.4193
1-Week Range:
$0.3971
$0.4582
52-Week Range:
$0.23
$2.75
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.4123 | 8.02M | 4.71M | -11.79M | -9.72M | -3.3492 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
Energy Focus, Inc. (EFOI) Latest Stock News & HeadlinesYahoo Finance - Yahoo! Finance Canada
Ensysce Biosciences, Inc. (ENSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ensysce Biosciences, Inc. (ENSC) Latest Stock News & Headlines - Yahoo! Finance Canada
Ensysce submits Phase 2a protocol for CRPS treatment CY200 - Investing.com
Ensysce submits Phase 2a protocol for CRPS treatment CY200 By Investing.com - Investing.com UK
Ensysce Biosciences Phase 2 Protocol for CY200A Neuroplastigen for the Treatment of CRPSSubmitted to the UK MHRA - Corsicana Daily Sun
A study plan for a pain condition with no treatment that cures it reaches UK regulators. - Stock Titan
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce hosts symposium at PainWeek, attends FDA hearing By Investing.com - Investing.com Canada
Ensysce hosts symposium at PainWeek, attends FDA hearing - Investing.com
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation - Corsicana Daily Sun
More than 320 pain professionals attended Ensysce’s symposium on complex pain. - Stock Titan
Ensysce Biosciences Inc (NASDAQ: ENSC) Share Price, ENSC Stock News, ENSC Share Price & Updates - kalkine.com.au
A doctor from Ensysce is among a limited group chosen to speak at an FDA psychedelic hearing - Stock Titan
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs - Corsicana Daily Sun
ORCL: Oracle Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
ENSC Q2 2026 Earnings: 60.78% EPS Beat Buys Optionality as Pre-Revenue Pipeline AdvancesEarnings Yield Analysis - dars.gov.et
An FDA hearing on psychedelic drugs is set for Sept. 14. Ensysce will take part. - Stock Titan
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation - Yahoo Finance
Ensysce completes PF614-MPAR-102 clinical enrollment - grafa.com
Ensysce completes enrollment in opioid overdose study By Investing.com - Investing.com Australia
Ensysce completes enrollment in opioid overdose study - Investing.com India
An opioid study from Ensysce is fully enrolled to test overdose protection - stocktitan.net
Ensysce Faces Nasdaq Delisting Risk After Cy Biopharma Deal Triggers Change of Control - minichart.com.sg
Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period - The Globe and Mail
Ensysce Biosciences raises $21M in initial tranche, meets Nasdaq equity rules, seeks second bid-price grace period - TradingView
Ensysce (ENSC) completes private raise with contingent proceeds - Stock Titan
Ensysce (ENSC) Results Versus Estimates: The Bottom-Line Figure Beats Its Comparison in the Latest Reading; After Earnings: The Stock Ends Down 3.87% for the Current SessionEarnings Yield Spread - vinanet.vn
Ensysce (ENSC) chair boosts stake, locks in votes on merger - Stock Titan
ENSC: Acquisition and financing position CY200 for CRPS advancement, extending cash runway to 2027 - TradingView
ENSC: Acquisition and financing position CY200 for Phase II CRPS trial and long-term pipeline growth - TradingView
Ensysce Biosciences director Gower buys $444,169 in company stock - Investing.com
Ensysce Biosciences Insider Bought Shares Worth $444,169, According to a Recent SEC Filing - marketscreener.com
Ensysce Biosciences (ENSC) director buys stock and converts debt - Stock Titan
Ensysce Biosciences earnings beat by $0.51, revenue fell short of estimates - Investing.com Canada
MSN Money - MSN
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
Ensysce Completes Cy Biopharma Acquisition Adding Lead CRPS Candidate - Minichart
Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com Australia
Ensysce Q2 EPS beats; completes Cy Biopharma acquisition for $38.6m - scanx.trade
Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal - Stock Titan
Ensysce Biosciences Q2 net loss widens on higher R&D costs - TradingView
ENSC: Acquisition and new funding extend cash runway, with clinical pipeline and losses both increasing - TradingView
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - FinancialContent
ENSC Q1 2026 Earnings: Narrower-than-Expected Loss Marks 30% Beat Amid Persistent Share Weakness - vinanet.vn
Cy Biopharma merges with Ensysce Biosciences - Startupticker.ch
Ensysce Biosciences (ENSC) officer reports 154.8M underlying common via preferred - Stock Titan
Ensysce Biosciences Acquires Cy Biopharma to Expand Pain Pipeline - sekbernews.id
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):